Elite receives FDA OK for generic Vyvanse
Generic Vyvanse is indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Elite received approval from the Food and Drug Administration for a generic version of Vyvanse (lisdexamfetamine dimesylate) capsules in strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg.
The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder.
[Read more: What is the state of the generics industry?]
IQVIA reported annual sales for the 12 months ending September 2024 of $4.3 billion for the brand and generic market for this product.